Advertisement
Screener

Moderna, Inc. (MRNA) Increase (Decrease) in Other Operating Liabilities

2.8 / 5 stars · 68/120 Roast Me

Moderna, Inc. Increase (Decrease) in Other Operating Liabilities

Moderna, Inc. (MRNA) reported Increase (Decrease) in Other Operating Liabilities of -$27.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2026-07-31

  • Moderna, Inc. increase (decrease) in other operating liabilities for the quarter ending 2026-06-30 was -$53.00M.
  • Moderna, Inc. increase (decrease) in other operating liabilities for the quarter ending 2026-03-31 was $26.00M, a 21.21% decline year-over-year.
  • Moderna, Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-12-31 was $131.00M, a 7.09% decline year-over-year.
  • Moderna, Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-09-30 was -$112.00M, a 2900.00% decline year-over-year.
  • Moderna, Inc. increase (decrease) in other operating liabilities for fiscal 2025 was -$6.00M, a 107.69% decline from fiscal 2024.
  • Moderna, Inc. increase (decrease) in other operating liabilities for fiscal 2024 was $78.00M, a 11.36% decline from fiscal 2023.
  • Moderna, Inc. increase (decrease) in other operating liabilities for fiscal 2023 was $88.00M.
  • Moderna, Inc. increase (decrease) in other operating liabilities for fiscal 2022 was -$740.00M, a 701.63% decline from fiscal 2021.
Period endIncrease (Decrease) in Other Operating Liabilities 3 monthIncrease (Decrease) in Other Operating Liabilities 3 month as first filedIncrease (Decrease) in Other Operating Liabilities 6 monthIncrease (Decrease) in Other Operating Liabilities 6 month as first filedIncrease (Decrease) in Other Operating Liabilities 9 monthIncrease (Decrease) in Other Operating Liabilities 9 month as first filedIncrease (Decrease) in Other Operating Liabilities 12 monthIncrease (Decrease) in Other Operating Liabilities 12 month as first filed
2026-06-30-$53.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31
-$27.00M
10-Q · filed 2026-07-31
$104.00M
derived: sum of 3 quarters · filed 2026-07-31
-$8.00M
derived: sum of 4 quarters · filed 2026-07-31
2026-03-31$26.00M
10-Q · filed 2026-05-01
$157.00M
derived: sum of 2 quarters · filed 2026-05-01
$45.00M
derived: sum of 3 quarters · filed 2026-05-01
-$13.00M
derived: sum of 4 quarters · filed 2026-07-31
2025-12-31$131.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20
$19.00M
derived: sum of 2 quarters · filed 2026-02-20
-$39.00M
derived: sum of 3 quarters · filed 2026-07-31
-$6.00M
10-K · filed 2026-02-20
2025-09-30-$112.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$170.00M
derived: sum of 2 quarters · filed 2026-07-31
-$137.00M
10-Q · filed 2025-11-06
$4.00M
derived: sum of 4 quarters · filed 2026-07-31
2025-06-30-$58.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31
-$25.00M
10-Q · filed 2026-07-31
$116.00M
derived: sum of 3 quarters · filed 2026-07-31
$120.00M
derived: sum of 4 quarters · filed 2026-07-31
2025-03-31$33.00M
10-Q · filed 2026-05-01
$174.00M
derived: sum of 2 quarters · filed 2026-05-01
$178.00M
derived: sum of 3 quarters · filed 2026-05-01
-$8.00M
derived: sum of 4 quarters · filed 2026-05-01
2024-12-31$141.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20
$145.00M
derived: sum of 2 quarters · filed 2026-02-20
-$41.00M
derived: sum of 3 quarters · filed 2026-02-20
$78.00M
10-K · filed 2026-02-20
2024-09-30$4.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$182.00M
derived: sum of 2 quarters · filed 2025-11-06
-$63.00M
10-Q · filed 2025-11-06
-$5.00M
10-Q · filed 2024-11-07
$4.00M
derived: sum of 4 quarters · filed 2026-02-20
2024-06-30-$186.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01
-$67.00M
10-Q · filed 2025-08-01
-$11.00M
10-Q · filed 2024-08-01
$0.00
derived: sum of 3 quarters · filed 2026-02-20
$39.00M
derived: sum of 4 quarters · filed 2026-02-20
2024-03-31$119.00M
10-Q · filed 2025-05-01
$130.00M
10-Q · filed 2024-05-02
$186.00M
derived: sum of 2 quarters · filed 2026-02-20
$225.00M
derived: sum of 3 quarters · filed 2026-02-20
$222.00M
derived: sum of 4 quarters · filed 2026-02-20
2023-12-31$67.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20
$106.00M
derived: sum of 2 quarters · filed 2026-02-20
$103.00M
derived: sum of 3 quarters · filed 2026-02-20
$88.00M
10-K · filed 2026-02-20
$73.00M
10-K · filed 2024-02-23
2023-09-30$39.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
$36.00M
derived: sum of 2 quarters · filed 2024-11-07
$21.00M
10-Q · filed 2024-11-07
-$992.00M
derived: sum of 4 quarters · filed 2025-02-21
2023-06-30-$3.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01
-$18.00M
10-Q · filed 2024-08-01
-$1.03B
derived: sum of 3 quarters · filed 2025-02-21
-$1.02B
derived: sum of 4 quarters · filed 2025-02-21
2023-03-31-$15.00M
10-Q · filed 2024-05-02
-$1.03B
derived: sum of 2 quarters · filed 2025-02-21
-$1.02B
derived: sum of 3 quarters · filed 2025-02-21
-$790.00M
derived: sum of 4 quarters · filed 2025-02-21
2022-12-31-$1.01B
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21
-$1.00B
derived: sum of 2 quarters · filed 2025-02-21
-$775.00M
derived: sum of 3 quarters · filed 2025-02-21
-$740.00M
10-K · filed 2025-02-21
$88.00M
10-K · filed 2023-02-24
2022-09-30$10.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03
$238.00M
derived: sum of 2 quarters · filed 2023-11-03
$273.00M
10-Q · filed 2023-11-03
$373.00M
derived: sum of 4 quarters · filed 2024-02-23
2022-06-30$228.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03
$263.00M
10-Q · filed 2023-08-03
$363.00M
derived: sum of 3 quarters · filed 2024-02-23
$323.00M
derived: sum of 4 quarters · filed 2024-02-23
2022-03-31$35.00M
10-Q · filed 2023-05-04
$135.00M
derived: sum of 2 quarters · filed 2024-02-23
$95.00M
derived: sum of 3 quarters · filed 2024-02-23
$155.00M
derived: sum of 4 quarters · filed 2024-02-23
2021-12-31$100.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23
$60.00M
derived: sum of 2 quarters · filed 2024-02-23
$120.00M
derived: sum of 3 quarters · filed 2024-02-23
$123.00M
10-K · filed 2024-02-23
2021-09-30-$40.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
$20.00M
derived: sum of 2 quarters · filed 2022-11-03
$23.00M
10-Q · filed 2022-11-03
$24.00M
derived: sum of 4 quarters · filed 2023-02-24
2021-06-30$60.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03
$63.00M
10-Q · filed 2022-08-03
$440.00M
10-Q · filed 2021-08-05
$64.00M
derived: sum of 3 quarters · filed 2023-02-24
$67.00M
derived: sum of 4 quarters · filed 2023-02-24
2021-03-31$3.00M
10-Q · filed 2022-05-04
$93.00M
10-Q · filed 2021-05-06
$4.00M
derived: sum of 2 quarters · filed 2023-02-24
$7.00M
derived: sum of 3 quarters · filed 2023-02-24
$5.00M
derived: sum of 4 quarters · filed 2023-02-24
2020-12-31$1.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24
$4.00M
derived: sum of 2 quarters · filed 2023-02-24
$2.00M
derived: sum of 3 quarters · filed 2023-02-24
$8.00M
10-K · filed 2023-02-24
$5.99M
10-K · filed 2021-02-26
2020-09-30$3.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04
$1.00M
derived: sum of 2 quarters · filed 2021-11-04
$7.00M
10-Q · filed 2021-11-04
$6.68M
10-Q · filed 2020-10-30
$1.15M
derived: sum of 4 quarters · filed 2022-02-25
2020-06-30-$2.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
$4.00M
10-Q · filed 2021-08-05
$4.41M
10-Q · filed 2020-08-06
-$1.85M
derived: sum of 3 quarters · filed 2022-02-25
-$2.67M
derived: sum of 4 quarters · filed 2022-02-25
2020-03-31$6.00M
10-Q · filed 2021-05-06
$5.73M
10-Q · filed 2020-05-07
$153.00K
derived: sum of 2 quarters · filed 2022-02-25
-$674.00K
derived: sum of 3 quarters · filed 2022-02-25
-$811.00K
derived: sum of 4 quarters · filed 2022-02-25
2019-12-31-$5.85M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25
-$6.67M
derived: sum of 2 quarters · filed 2022-02-25
-$6.81M
derived: sum of 3 quarters · filed 2022-02-25
-$6.00M
10-K · filed 2022-02-25
-$6.17M
10-K · filed 2020-02-27
2019-09-30-$827.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30
-$964.00K
derived: sum of 2 quarters · filed 2020-10-30
-$153.00K
10-Q · filed 2020-10-30
$1.62M
10-Q · filed 2019-11-06
-$97.00K
derived: sum of 4 quarters · filed 2021-02-26
2019-06-30-$137.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
$674.00K
10-Q · filed 2020-08-06
$53.00K
10-Q · filed 2019-08-08
$730.00K
derived: sum of 3 quarters · filed 2021-02-26
$792.00K
derived: sum of 4 quarters · filed 2021-02-26
2019-03-31$811.00K
10-Q · filed 2020-05-07
$484.00K
10-Q · filed 2019-05-09
$867.00K
derived: sum of 2 quarters · filed 2021-02-26
$929.00K
derived: sum of 3 quarters · filed 2021-02-26
$1.54M
derived: sum of 4 quarters · filed 2021-02-26
2018-12-31$56.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26
$118.00K
derived: sum of 2 quarters · filed 2021-02-26
$727.00K
derived: sum of 3 quarters · filed 2021-02-26
$910.00K
10-K · filed 2021-02-26
2018-09-30$62.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06
$671.00K
derived: sum of 2 quarters · filed 2019-11-06
$854.00K
10-Q · filed 2019-11-06
2018-06-30$609.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08
$792.00K
10-Q · filed 2019-08-08
2018-03-31$183.00K
10-Q · filed 2019-05-09
2017-12-31-$145.00K
10-K · filed 2020-02-27
2016-12-31$1.98M
10-K · filed 2019-03-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Revolution Medicines, Inc. (RVMD)United States$42.805B-22.69
BIOGEN INC. (BIIB)United States$33.427B19.60
EXELIXIS, INC. (EXEL)United States$14.358B16.15
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69